ERBB2 and breast cancer: The extracellular domain of HER2 can be cleaved from the surface of breast cancer cells by matrix metalloproteases [3] and released into the serum, where it is detectable using a monoclonal antibody directed against the extracellular domain of the HER2 antigen.